State Street’s Y-mAbs Therapeutics YMAB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-780,145
| Closed | -$3.52M | – | 4386 |
|
|
2025
Q2 | $3.52M | Sell |
780,145
-8,876
| -1% | -$39.9K | ﹤0.01% | 3087 |
|
|
2025
Q1 | $3.5M | Sell |
789,021
-525,388
| -40% | -$3.05M | ﹤0.01% | 3025 |
|
|
2024
Q4 | $10.3M | Buy |
1,314,409
+104,628
| +9% | +$1.27M | ﹤0.01% | 2620 |
|
|
2024
Q3 | $15.9M | Buy |
1,209,781
+405,169
| +50% | +$5.14M | ﹤0.01% | 2345 |
|
|
2024
Q2 | $9.72M | Buy |
804,612
+53,539
| +7% | +$723K | ﹤0.01% | 2576 |
|
|
2024
Q1 | $12.2M | Sell |
751,073
-10,459
| -1% | -$141K | ﹤0.01% | 2457 |
|
|
2023
Q4 | $5.19M | Buy |
761,532
+20,434
| +3% | +$118K | ﹤0.01% | 2928 |
|
|
2023
Q3 | $4.04M | Sell |
741,098
-3,509
| -0.5% | -$20.4K | ﹤0.01% | 3027 |
|
|
2023
Q2 | $5.06M | Sell |
744,607
-18,223
| -2% | -$137K | ﹤0.01% | 2992 |
|
|
2023
Q1 | $3.82M | Sell |
762,830
-69,321
| -8% | -$283K | ﹤0.01% | 3092 |
|
|
2022
Q4 | $4.06M | Sell |
832,151
-1,086,988
| -57% | -$7.9M | ﹤0.01% | 3124 |
|
|
2022
Q3 | $27.7M | Buy |
1,919,139
+175,997
| +10% | +$2.91M | ﹤0.01% | 1994 |
|
|
2022
Q2 | $26.4M | Sell |
1,743,142
-565,640
| -24% | -$6.6M | ﹤0.01% | 2053 |
|
|
2022
Q1 | $27.4M | Buy |
2,308,782
+852,112
| +58% | +$8.75M | ﹤0.01% | 2168 |
|
|
2021
Q4 | $23.6M | Buy |
1,456,670
+124,727
| +9% | +$2.67M | ﹤0.01% | 2352 |
|
|
2021
Q3 | $38M | Sell |
1,331,943
-57,568
| -4% | -$1.81M | ﹤0.01% | 2009 |
|
|
2021
Q2 | $47M | Sell |
1,389,511
-319,910
| -19% | -$10.3M | ﹤0.01% | 1891 |
|
|
2021
Q1 | $51.7M | Buy |
1,709,421
+766,418
| +81% | +$31.4M | ﹤0.01% | 1727 |
|
|
2020
Q4 | $46.7M | Sell |
943,003
-106,933
| -10% | -$4.95M | ﹤0.01% | 1682 |
|
|
2020
Q3 | $40.3M | Buy |
1,049,936
+94,347
| +10% | +$3.75M | ﹤0.01% | 1608 |
|
|
2020
Q2 | $41.3M | Buy |
955,589
+167,194
| +21% | +$6.32M | ﹤0.01% | 1572 |
|
|
2020
Q1 | $20.6M | Buy |
788,395
+40,279
| +5% | +$1.17M | ﹤0.01% | 1821 |
|
|
2019
Q4 | $23.4M | Buy |
748,116
+394,181
| +111% | +$11.7M | ﹤0.01% | 2035 |
|
|
2019
Q3 | $9.22M | Buy |
353,935
+31,878
| +10% | +$814K | ﹤0.01% | 2510 |
|
|
2019
Q2 | $7.37M | Buy |
322,057
+239,895
| +292% | +$5.51M | ﹤0.01% | 2632 |
|
|
2019
Q1 | $2.15M | Buy |
82,162
+16,765
| +26% | +$368K | ﹤0.01% | 3124 |
|
|
2018
Q4 | $1.33M | Buy |
+65,397
| New | +$1.5M | ﹤0.01% | 3260 |
|
Other funds holding YMAB
State Street's YMAB Position: Q3 2025 in Review
State Street sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 780,145 shares — an estimated $3.52M sold.
State Street first reported a position in YMAB in Q4 2018 and held it in 27 quarters. The position peaked at $51.7M in Q1 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.
- State Street reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
- State Street sold 780,145 Y-mAbs Therapeutics shares in Q3 2025, an estimated $3.52M.
- State Street first reported a position in Y-mAbs Therapeutics in Q4 2018 and held it in 27 quarters.
- State Street's Y-mAbs Therapeutics position peaked at $51.7M in Q1 2021.
- 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.
Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.